The mainstay of treatment for metastatic PCa is androgen deprivation therapy (ADT), but resistance ultimately develops with progression to castration-resistant prostate cancer (CRPC), which typically harbors a “luminal” (adenocarcinoma) phenotype (CRPC-Adeno) with continued dependence on androgen receptor (AR) signaling3–5. The gene discussed is AR; the disease is posterior cortical atrophy.